Updates

2026-05-11

Updates from client review

• Home pillar trio is now Efficacy / Safety / Dosing. Putting Efficacy in MOA's old slot does two jobs at once: it answers the “drop MOA from the three buckets” ask, and the Efficacy card's blurb names DREAMM-7 and DREAMM-8 directly — so the post-creative area already echoes the “studied in two trials” callout, partially covering the ask to fold an efficacy data point into that section while we wait on the new journal ad for a hard stat.
• Patient profiles teaser on the home page reframed to land the “wide range of patient types” message.
• “Efficacy data” renamed to “Efficacy” in the main nav.
• “Eye-related side effects” promoted to a top-level nav item.
• Nav dropdowns removed — top nav is now flat.
• Efficacy page: inclusion / exclusion criteria folded into the Study design section.
• Safety page rebuilt as a waterfall — adverse reactions, eye-related side effects, and eye care management now live on a single page (sub-pages retired).
• Dosing page rebuilt as a waterfall — starting dose, modifications, and administration now live on a single page (sub-pages retired).
• “On this page” sidebar added to Efficacy, Safety, and Dosing — sticky on desktop, collapses to a dropdown at the top on mobile, highlights the active section as you scroll.
• Resources cards now have a 16:9 thumbnail tile with an 8.5×11 portrait placeholder floating centered inside (reads as a doc cover sitting on a tile).